Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Authors
Tareq Al Baghdadi
Michigan Cancer Research Consortium, IHA Hematology Oncology, Ypsilanti, MI
Tareq Al Baghdadi , Michael Rothe , Pam K. Mangat , Elizabeth Garrett-Mayer , Kathleen J Yost , Vi Kien Chiu , Herbert Leon Duvivier , Meredith McKean , Jens Rueter , Mark A. Taylor , Gina N. Grantham , Abby Gregory , Dominique C. Hinshaw , Susan Halabi , Richard L. Schilsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02693535
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 308)
DOI
10.1200/JCO.2024.42.3_suppl.308
Abstract #
308
Poster Bd #
E8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: Timothy Lewis Cannon
Poster
2023 ASCO Annual Meeting
Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: Gordan Srkalovic
Poster
2022 ASCO Annual Meeting
Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
First Author: Gordan Srkalovic